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Abstract: Osteoporosis is by far the most frequent metabolic disease affecting bone. Current clinical 
therapeutic treatments are not able to offer long-term solutions. Most of the clinically used anti-
osteoporotic drugs are administered systemically, which might lead to side effects in non-skeletal 
tissues. Therefore, to solve these disadvantages, researchers have turned to nanotechnologies and 
nanomaterials to create innovative and alternative treatments. One of the innovative approaches to 
enhance osteoporosis therapy and prevent potential adverse effects is the development of bone-
targeting drug delivery technologies. It minimizes the systemic toxicity and also improves the 
pharmacokinetic profile and therapeutic efficacy of chemical drugs. This paper reviews the current 
available bone targeting drug delivery systems, focusing on nanoparticles, proposed for osteoporosis 
treatment. Bone targeting delivery systems is still in its infancy, thus, challenges are ahead of us, 
including the stability and the toxicity issues. Newly developed biomaterials and technologies with 
potential for safer and more effective drug delivery, require multidisciplinary collaboration between 
scientists from many different areas, such as chemistry, biology, engineering, medicine, etc, in order 
to facilitate their clinical applications. 
Keywords: nanoparticles; osteoporosis; drug delivery system; anti-osteoporotic drugs; osteoclast; 
osteoblast; bone-targeting  
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1. Introduction 
1.1. Osteoporosis 
Osteoporosis is a progressive skeletal disease characterized by reduced bone mass and 
microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and 
susceptibility to fracture. According to the definition given by the World Health Organization, 
osteoporosis is diagnosed when a patient has a bone mineral density of 2.5 standard deviations or 
more below the average value of bone mass for young healthy adults [1]. In adults, bone is 
remodeled by a coordinated process in which bone resorbing osteoclasts remove old bone, and bone-
forming osteoblasts synthesize and mineralize new bone matrix [2]. Disturbances in this 
physiological process lead to a decreased bone mass, namely, osteoporosis. Unfortunately, the 
current treatments for osteoporosis have notable restrictions, including adequacy and long-term 
safety issues [3]. It does not exist yet a satisfactory solution to the problem of bone weakening due to 
osteoporosis [4]. The treatment options of osteoporosis are limited to anti-resorptive drugs, that slow 
down the excess of bone resorption (principal cause of primary osteoporosis); and anabolic agents, 
that effectively increase the bone mass that has previously disappeared as a consequence of 
resorption excess [5]. With increased aging population and life expectancy, bone diseases have 
become the most prevalent degenerative disorders and a major public health problem in many 
countries [6,7], which has fuelled the interest in prevention and treatment. According to the 
International Osteoporosis Foundation, osteoporosis is estimated to affect one in three women and 
one in five men over the age of 50 years [8]. In fact, a bone will break every 3 seconds because of 
this disease. This problem has an enormous human and socio-economic impact. In the European 
Union, the economic burden of incidents and prior fragility fractures mainly due to osteoporosis was 
estimated at €29 billion in the five largest EU countries (France, Germany, Italy, Spain and UK) and 
€38,7 billion in the 27 EU countries [9].  
1.2. Current treatments for osteoporosis 
Therapeutic strategies to limit bone loss and prevent fracture are predominantly divided in two 
main groups (Figure 1) [9], anti-resorptive drugs, that target osteoclasts, and bone forming  
 
Figure 1. Schematic diagram about the different approaches of osteoporosis treatment. 
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accelerators or anabolic drugs, designed for osteoblast stimulation [10]. Anti-resorptive drugs act 
mainly by suppressing osteoclast activity preserving bone mass and increasing bone strength [4,11]. 
On the other hand, anabolic drugs are able to induce bone formation and can reverse bone 
deterioration generated by the osteoporosis progression [4,12].  
1.2.1. Anti-resorptive drugs 
In the last few years osteoporosis therapeutics have been monopolized by bisphosphonates (BP) 
capable of averting further bone degradation in well-established osteoporosis [13]. BP disrupts 
osteoclast activity by inhibiting farnesyl pyrophosphate synthase, critical enzyme for membrane 
protein prenylation and osteoclast detachment from bone [14]. Ultimately, they induce osteoclast 
apoptosis, thus reducing bone resorption [15]. Even though they are capable of reducing the fracture 
risk and bone turn over, the effect of these drugs in increasing or recovering bone mass is really 
small, at < 2% per year [16]. Furthermore, BP are not easily absorbed by intestine, presenting 
variable bioavailability, being necessary to ingest the drug 2 hours before breakfast and avoid the 
administration of a second drug for 30 minutes in order to minimize the interactions with cations like 
calcium, iron, etc. [13]. It is necessary to orally administrate high doses, what causes several side 
effects like esophagitis [3], due to the local action on the mucosa, or jaw necrosis due to an excessive 
inhibition of bone resorption [17]. Taking this into consideration, it is relevant to know about long-
term treatment with bisphosphonates. Clinical studies have examined the effects of using 
bisphosphonates in treatments of 3, 5 or 10 years. They showed a persistent antifracture and bone 
mineral density increasing effects beyond 3 years of treatment [18]. On the other hand, more serious 
adverse effects, or discontinuation due to adverse effects were reported between patients with 10 
years treatment versus those with just 5 years treatment [19].  
Another anti-resorptive drug is raloxifene (RLX). RLX is a second generation non-steroidal 
benzothiophene, selective estrogen receptor modulator (SERM). It acts as estrogen agonist in bone. 
RLX reduces bone loss by inhibiting the activity of cytokines which increase bone resorption. 
Although RLX is rapidly absorbed by the intestine, it will suffer an extensive pre-systemic 
glucuronide conjugation. Consequently, the absolute bioavailability achieved is very low.  
Osteoclast differentiation is triggered when Receptor Activator of Nuclear Factor κB  
ligand (RANKL) binds to its receptor, RANK, present on the surface of osteoclasts and osteoclast 
precursors [20]. This interaction will promote osteoclast differentiation through preosteoclast fusion 
and osteoclast survival. Consequently, it generates multinucleated mature bone-resorbing osteoclasts, 
which increment the bone resorption rate [2,10,20]. According to this concept, a monoclonal 
humanized anti-RANKL antibody has been developed and currently used as osteoporosis  
therapy [10]. 
1.2.2. Anabolic drugs 
Recombinant human parathyroid hormone (rPTH) [21] and estrogens [22] are anabolic agents 
for bone formation that have demonstrated their efficacy in osteoporosis [5,22,23]. rPTH by daily 
administration has proven to be more efficient than BP therapy by increasing bone mass. This drug is 
used for its capability of stimulating bone formation [24] and for its ability to suppress apoptosis of 
osteoblasts [25]. However, the increased hypercalcemic and tumor risk associated with prolonged 
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hormone administration, and need for daily injections, limits the long-term treatment to  
24 months [26]. 
Another way explored to promote bone formation is the administration of growth factors like 
bone morphogenetic proteins (BMPs). They stimulate bone formation and increase bone strength and 
density [5,27]. However, supraphysiological doses are necessary to achieve therapeutic effects, what 
can lead to undesirable effects such as uncontrolled bone formation, inflammation or even 
tumorigenesis [28]. Furthermore, the short half-life of BMPs limited their systemic  
administration [29]. 
More recently, gene silencing through the delivery of small interfering RNA (siRNA) has been 
used as treatment for bone disease such as osteoporosis. Due to the several advantages that this 
therapy presents, its study has increased notably [30]. In this type of therapy, siRNA targeted those 
genes that had been identified to down regulate bone formation without modulating bone resorption. 
However, high doses of siRNA are necessary to sufficiently stimulate bone formation, what drives to 
a high risk for adverse effects in non-skeletal tissues [31].  
Taking these aspects into consideration, one of the most important and persistent problems of 
osteoporosis treatment is the several side effects of the different current drugs. It is clear that the 
development of specific delivery systems for each developed drug is necessary.  
2. Drug Delivery and Bone Release by Nanotechnology 
Drugs delivered systemically are absorbed into the blood stream and distributed through the 
body. They are rapidly clear from the body and poorly penetrate into bone tissue. Bone compared to 
other organs like brain, liver, or kidney is less vascularized which is the principal reason why drugs 
penetrate less in bone than in other tissues [32]. Thus, they are generally administered in a high dose 
or/and frequently, what can result in systemic toxicity. It would be safer and more effective if the 
drug could be delivered specifically to bone tissue through a controllable drug delivery system [33]. 
Drug delivery systems (DDS) are designed for improving the therapeutic effect of drugs, minimizing 
their potential toxic side effects. In the last few years the use of nanoparticles as DDS applied to 
bone diseases has gained growing attention (Figure 2). The drug carrier would transport the drug to 
bone tissue, there releasing the therapeutic agent, which either promotes bone growth or reduces 
bone resorption. In this sense DDS optimize the drug doses, protect drug from biodegradation and 
reduce the drug exposure to non-target cells [23,34]. For example, during the treatment with estrogen, 
the distribution of the drug to other tissues different from bone can produce several effects such as 
intrauterine hemorrhage, increasing uterus weight or even endometrial and breast cancer [35,36]. 
Recent research developed an estradiol-prodrug, consisting of estradiol conjugated with an Asp-
oligopeptide carrier. They found that it was selective to bone, and even produced a long-term action 
on bone, avoiding the side effects of estradiol. The use of this selective bone delivery system would 
also extend medication intervals, resulting in a better quality of life for patients [37].  
A targeted drug delivery system is a system that releases the drug in a preselected site. The bone 
targeting moieties and the carriers are the most important elements in a drug delivery system 
targeting bone diseases [36]. 
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Figure 2. Number of publications with the terms “osteoporosis + nanoparticles” in Web 
of Science; (right) Number of publications with the terms “Nanoparticles + bone 
targeting” in Web of Science. 
2.1. Bone-targeting moieties 
In order to guide nanoparticles to bone, it is important to find moieties with strong affinity to it. 
It is known that bones are made of a mineralized matrix, being hydroxyapatite (HA) its principal 
component [38]. Since HA crystals are present in a high concentration in bone, it would represent a 
promising target for selective delivery [39]. Moieties with high affinity to HA should be taken into 
consideration.  
2.1.1. Tetracycline and bisphosphonate 
Tetracycline and bisphosphonate have strong affinity with the calcium present on HA, so they 
can be used as bone-targeting moieties [35]. Tetracycline was the first to be used because of its 
strong affinity with calcium. It is used as antibiotic but, due to the high affinity to bone it caused 
children teeth to stain yellow, so its use was discontinued in pediatric medicine. Despite this fact, its 
use as antibiotic in adults and as bone targeting moiety has persisted [40]. Consequently, smaller 
molecules with similar bind capacities as tetracycline were designed, as tetracycline analogues [41]. 
Neale et al. tried to reduce potential side effects caused by tetracycline's biological activity by 
minimalizing tetracycline structure. The modifications were still able to bind HA but did not retain 
the biological activity [42]. Despite these efforts, its complicated chemical structure and its poor 
stability during chemical modifications, pledged its use [36]. Unlike tetracycline, bisphosphonates 
have attracted the attention as bone-targeting moieties in recent years. They are widely used to treat 
the osteolysis diseases due to their high affinity to HA, their capacity to bind at sites with osteoclastic 
activity and their ability to inhibit bone resorption. These facts permit to use the same molecule for 
targeting and for treating the disease [14].  
2.1.2. Oligopeptides 
Furthermore, some studies found moieties capable of discriminating between bone-resorption 
surface and bone-formation surface. It has been reported that eight repeating sequences of  
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aspartate (Asp8) preferentially bind to bone-resorption surface, and (AspSerSer)6 showed favorable 
binding to bone-formation surface [31]. Thanks to this, it is possible to use one moiety or another 
depending on the type of drug used. If it is an antiresorptive agent, it should be used Asp8 which 
guides to bone resorption surface, or if it is an anabolic agent, it should be used instead (AspSerSer)6 
that should be guide instead to bone formation surface [43]. 
2.2. Nanocarriers in osteoporosis therapy 
In the last few years, nanoparticles have been found to be promising carriers for efficient 
therapeutic delivery in bone disease therapy. For bone regeneration in osteoporosis patients, the 
development of nanoparticles is ideal since bone itself is a nanocomposite. In addition to this 
dimensional similarity, they can offer drug protection from biodegradation, transport efficiency, and 
even improve its pharmacokinetic, pharmacodynamics, biodistribution and targeting [36]. Thanks to 
their capability to be chemically modified they can enhance therapeutic loading, increase tissue 
specificity, decreasing doses without sacrificing treatment efficacy [44]. 
Table 1. Summary of bone targeting drug delivery system with therapeutic activity. 
Therapy Bone targeting moiety Carrier Reference 
Thermolysis ALN Fe3O4 NPs [45] 
ALN ALN Gold NPs [17] 
RANKL siRNA AspSerSer6 Cationic Liposomes [46] 
ALN ALN HA NPs [47] 
RIS RIS ZnHA NPs [13] 
RANK siRNA * MBG´s [10] 
RLX * Chitosan NPs [23] 
Ethinylestradiol * Liposomes [48] 
*The targeting moiety is not specified; ALN: Alendronate RANKL: Receptor Activator for Nuclear Factor 
κB ligand siRNA: small interfering RNA RIS: Risedronate RLX: Raloxifene; Asp: Aspartate Ser: Serine; 
HA: Hydroxyapatite NPs: nanoparticles MBG: Mesoporous bioactive glass nanospheres. 
2.2.1. Organic nanoparticles for osteoporosis treatment 
(1) Liposomes 
Liposomes were the first nano-delivery system that succeeded in becoming a clinical 
application [49]. Generally, liposomes are made by the self-assembly of lipid molecules with a 
hydrophilic head group and hydrophobic tail. The addition of cholesterol reduces the membrane 
permeability, and then it improves the mechanical characteristics of the liposome [48,50]. This 
structure permits to have an aqueous core enclosed within a phospholipid bilayer that permits to load 
drugs with different solubility. Hydrophobic agents would be in the bilayer membrane, while 
hydrophilic agents would be in the aqueous core [51]. One of the biggest handicaps of liposomes is 
the rapid uptake by reticuloendothelial system (RES), which is traduced in a low circulation half-life. 
Incorporating polyethynel glycol-lipid (PEG-lipid) conjugated with the bilayer will decrease the 
uptake by RES so the time in blood stream will increase [52]. 
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During the last years a new generation of liposomes was created for the specific delivery of 
genes to treat bone diseases. Lu et al. prepared ethinylestradiol liposome (EEL) and investigated its 
action against postmenopausal osteoporosis using the ovarectomized rat model. They concluded that 
EEL, compared to free ethinylestradiol, were more effective in stimulating the amount of calcium 
deposition in bone, and also increasing the osteoblast activity and the active bone formation [48]. 
Zhang et al. linked (AspSerSer)6 with a cationic liposome which encapsulates an osteogenic siRNA. 
This siRNA targets a negative regulator of osteogenic lineage activity (Plekhol) [53]. Cationic 
liposomes are made of cationic lipids which have one or more amines present in the polar head. 
These liposomes bind and condense DNA spontaneously to form complexes with high affinity to cell 
membranes and capable of delivering the plasmids into the cells [54,55]. This permits the delivery of 
therapeutic cargos (e.g. siRNAs) to the target osteogenic-linage cells, as an alternative to the 
modulation of bone-resorption [31]. Compared to the cationic liposomes, neutral liposomes have 
lower toxicity, longer circulation half-life, and less interaction with proteins [53]. Neutrally charged 
lipoplexes can be implemented to the cationic liposome system in order to solve these problems. 
Similar to this, Hengst et al. designed liposomes and used cholesteryl-trisoxyethylenebisphosphonic 
acid (CHOL-TOE-BP), a new tailor-made bisphosphonate derivate, as bone targeting moiety. These 
liposomes were designed for the treatment of bone related diseases such as osteoporosis [56].  
(2) PLGA-nanoparticles 
Compared to liposomes, rigid nanoparticles are promising as delivery system because of their 
high capacity of cargo and their nano-size. Synthetic biodegradable polymers as poly-lactide (PLA) 
and the copolymer poly(lactide-co-glycolide) (PLGA) have been extensively used for the synthesis 
of nanoparticles [57], due to their excellent host biocompatibility, non-toxicity, and tuneable 
degradation rates [58]. It is possible to achieve different drug release profiles by modifying the 
molecular weight, the copolymer ratio, the particle size, the porosity, and the manufacturing 
conditions [34]. Another advantage of PLGA is that it can be functionalized and modified allowing 
the attachment of biological molecules [59]. Furthermore, it has been FDA-approved for a number of 
biomedical applications. PLGA properties such as swelling, the molecular interaction potential with 
the cargo [34], the controllable degradation period (about 1–6 months) [35] make it the perfect 
candidate for the design of controlled delivery systems. Jiang et al. have developed PLGA-based 
nanoparticles with a short sequence of poly-aspartic acids that have shown to interact exclusively 
with hard tissues. Fluorescein isothiocyanate (FITC) was tagged to the nanoparticles in order to 
study their distribution and binding capacity. The in vitro and ex vivo studies showed the exclusive 
binding affinity of FITC-poly-Asp nanoparticles to bone tissue [59]. The accumulation of the 
nanoparticles in bone niches permits a higher local drug concentration, reducing side effects and 
lengthening the therapeutic window. Similar to this, Fu et al. developed bone-targeting nanoparticles 
using PLGA-PEG copolymers and Aspn-based bone targeting moieties (1–3). Asp3-nanoparticles 
showed the best binding capacity to apatite [60]. Moreover, Cong et al. designed PLGA-PEG 
nanoparticles and functionalized with alendronate (ALN), which is a type of bisphosphonate, as bone 
targeting moiety [61]. 
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(3) Chitosan NP´s 
Chitosan is one of the most used polymers in drug delivery due to its properties like 
biocompatibility, non-toxicity and biodegradability with ecological safety [23]. Chitosan is a 
copolymer of β-(1-4) linked 2-acetamido-2-deoxy-β-D-glucopyranose and 2-amino-2-deoxy-β-D-
glycopyranose, is obtained by deacetylation of chitin which is widely distributed in nature. The 
presence of amino groups permits it to be protonated at low pH that makes it soluble in water. On the 
other hand, when the pH increases over 6 the chitosan amines become deprotonated so the polymer 
becomes insoluble [62]. Saini et al. prepared nanoparticles by an ionic gelation process of chitosan 
and tripolyphosphate (Figure 2) [23]. The interactions between the positive amino groups of chitosan 
and the negative charged tripolyphosphate caused the formation of the nanoparticles [63]. After that 
the drug raloxifene was loaded in the nanoparticles in order to achieve a new formulation for the 
intranasal delivery of raloxifene for osteoporosis therapy. Mucoadhesive nature of the polymer 
helped the nanoparticle in adhering to the nasal mucosa what permits the direct delivery of the drug 
to systemic circulation. Finally it was concluded that raloxifene loaded chitosan nanoparticles could 
be a novel drug delivery system for osteoporosis treatment [23]. 
2.2.2. Inorganic nanoparticles for osteoporosis treatment 
(1) Bioactive-silica nanoparticles 
Some studies have suggested a beneficial effect of dietary silica on skeletal development in  
rats [64]. Clinical studies revealed positive associations between dietary silica intake and bone 
mineral density (BMD) in human cohorts [65]. Silica is famous for being nontoxic in vivo below the 
concentration of 50,000 ppm without adverse effects in rats [2]. However the mechanisms by which 
silica affects skeletal development are unknown. Some studies postulated that silica nanoparticles 
would be bioactive and beneficial to the skeleton [2]. Beck et al. examined the effect of 50 nm silica-
based nanoparticles on the differentiation of osteoclast and osteoblast. The authors of the study 
finally revealed that the nanoparticles were biologically active; they suppress osteoclast 
differentiation and stimulate osteoblast differentiation and mineralization in vitro. However, the 
exact mechanisms are not completely understood. The nuclear factor kappaB (NF-κB) is a 
transcription factor necessary for osteoclast differentiation [66], and a potent inhibitor of osteoblast 
differentiation and activity [67]. Therefore, antagonists of NF-κB will promote osteoblast 
differentiation and will suppress osteoclast formation [68]. It is true that these nanoparticles suppress 
NF-κB signaling after 24 hours, what could be a partial explanation of how nanoparticles may 
regulate osteoclast and osteoblast differentiation [2]. Furthermore, in vivo nanoparticles have the 
capacity to increase BMD in mice, suggesting their possible application in osteoporosis treatment [2]. 
Recently, Ha et al. investigated the cellular mechanism by which silica-based nanoparticles stimulate 
differentiation and mineralization of osteoblasts. They revealed that nanoparticles are internalized by 
caveolae-mediated endocytosis, stimulate ERK1/2 signaling pathway, which is necessary for the 
processing of LC3β-I to LC3β-II, stimulating the autophagosome assembly. Although it is not 
completely understood, this process is stimulatory to osteoblast differentiation and  
mineralization [69]. This conclusion is supported by a recent study which found that the inhibition of 
the autophagosome formation blocked bone mineralization [70]. 
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Mesoporous silica nanoparticles (MSNs) have been also reported as a drug delivery  
system [71,72]. In 2001, the mesoporous material MCM-41 was proposed for the first time as  
DDS [73]. Sun et al. fabricated MSNs anchored by zolendronate for targeting bone sites, which can 
be used as DDS of antiosteoporotic drugs [74]. Gene silencing through delivering small interfering 
RNA (siRNA) has a lot of advantages due to the intrinsic nature of RNA interference (RNAi). 
SiRNA interferes reducing the expression of a specific gene. This technique has gained great 
potential as bone disease therapy enhancing bone tissue formation [30]. Among different silica-based 
nanoparticles, MSNs have great potential to deliver molecules like siRNA. Generally, siRNAs have 
very short half-life, poor capacity of penetration through the cell membranes, and are immediately 
degraded by RNase [10]. Consequently, more research is necessary in order to find a nanocarrier 
which can solve these problems. Because of their unique properties like, large surface area, surface 
functionality, tunable pore size, loading capacity, and biocompatibility, MSN study as potential 
delivery systems for genetic molecules have increased [75,76]. Mesoporous bioactive glass 
nanospheres (MBG) are a type of calcium-added MSNs. They have potential applications for hard 
tissue repairs and regeneration. Kim et al. demonstrated a novel therapeutic application in which 
MBGs suppress osteoclastic functions by delivering RANK siRNA [10]. 
(2) Metal nanoparticles 
Thermotherapy has been attractive for the treatment of osteoporosis. It is capable of generating 
cell death by disrupting cell membranes and denaturing intracellular proteins [77]. It has been used in 
order to control osteoporosis by destroying osteoclasts through thermolysis. Iron (II, III)  
oxide (Fe3O4) nanoparticles are chemically stable, nontoxic, and cost efficient. They have a high 
magnetic field that can be used to increase local temperature, and in this way trigger osteoclast 
regulation [78]. Lee et al. synthesized nanoparticles of Fe3O4 by co-precipitation and then coated 
them with dextran (Dex), in order to increase nanoparticle dispersion in aqueous solvents [45]. After 
that, to acquire the capacity to bind bone surface, they grafted ALN onto magnetic nanoparticles. 
ALN has two principal groups, an amino group, responsible for the inhibition of osteoclast activity, 
and a bisphosphonate group which has high affinity to bone hydroxyapatite. The amino group is 
responsible for the main side effects observed, namely nausea, abdominal discomfort or vomiting. 
Thus, they inactivated that group by grafting it with the nanoparticles. Consequently, the 
ALN/Dex/Fe3O4 nanoparticles have affinity to bone, can be phagocyted by osteoclasts, and then by 
radiofrequency induce thermolysis and cause osteoclast death [45].  
Other metal nanoparticles, like gold nanoparticles, have been studied for osteoporosis 
applications. Recent studies reported that gold nanoparticles can promote osteoblast differentiation 
and inhibit osteoclast differentiation [17,79]. Choi et al. reported that chitosan-conjugated-gold 
nanoparticles at nontoxic concentrations (1 ppm) stimulate osteogenic differentiation of human 
adipose-derived mesenchymal stem cells (hADMSCs). According to their results, mechanical 
stimulation by uptake of chitosan-conjugated AuNPs in hADMSCs enhances its differentiation into 
osteoblasts through the activation of the Wnt/β-catenin signaling pathway. Consequently, the 
accumulation of β-catenin promotes the differentiation of hADMSCs to osteoblast [79]. Lee et al. 
showed that 30 nm gold nanoparticles conjugated with ALN have a synergistic effect of inhibiting 
osteoclast differentiation [17]. As we mentioned previously RANKL is a determinant factor for 
osteoclasts differentiation, and reactive oxygen species (ROS) play an important role in this  
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respect [80]. Gold nanoparticles reduce the production of ROS by RANKL and also increase the 
expression of glutathione peroxidase-1 [81], both actions suppress osteoclast formation [82]. 
(3) Hydroxyapatite nanoparticles 
HA is a bio-mineral, one of the principal constituents of human bones matrix and teeth. HA is 
biocompatible, biodegradable, and has excellent osteoconductive properties [83]. Early studies 
demonstrated that nano-sized HA promotes osteoblast bioactivity, enhancing bone  
regeneration [84,85]. In this regard, nanocarrier itself helps bone tissue to grow, and increases bone 
mass deposition. Hwang et al. [47] designed HA-based nanoparticles which can deliver drugs and 
bone mineral to bone tissue. In order to functionalize nanoparticles surface, they were coated by a 
layer-by-layer method with three layers of poly (allylamine) (PAA) and alginate (ALG) (Figure 3). 
Then, at the outmost layer, ALN was conjugated, which confers the capacity to bind bone tissue. 
ALN was used as a targeting moiety and also as anti-resoprtive drug. The HA acts like a core for the 
nanoparticles, and when they arrive to bone matrix they increase bone density by inducing 
osteoconduction [47]. 
 
Figure 3. Schematic design of ALN-LbL-HA NPs. 
Some studies reported that HA-based nanoparticles loaded with risendronate (RIS), which is a 
bisphosphonate, increase bone density and improve stiffness and strength of bone. Compared to the 
administration of RIS alone, HA-based nanoparticles loaded with RIS were much efficient, even 
with lower concentrations of RIS, which reduced side effects [83]. Khajuria et al. chose zinc-
hydroxyapatite (ZnHA) to design their nanoparticles [13]. They decided to dop the HA with zinc. 
Since several studies demonstrated that zinc-HA enhanced HA bioactivity. Zinc shares properties 
with calcium, so it can replace calcium in HA and therefore in bone. Zinc enhances bone growth and 
bone mineralization by stimulating osteogenesis of osteoblasts, represses osteoclast function [68] and 
improves bone protein synthesis [86]. However, it is important to know that concentrations over  
225 mg of zinc generate cytotoxic effects [87]. These ZnHA-based nanoparticles were loaded with 
RIS in order to achieve bone targeting. The results demonstrated that ZnHA/RIS nanoparticles 
present a therapeutic advantage over pure RIS or HA/RIS nanoparticles [13]. 
 
 
Layer
by
Layer
Polyallylamine
Sodium alginate
Alendronate
HA NPs
LbL-HA-NPs
ALN-LbL-HA NPs
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Table 2. Summary of advantages and disadvantages of different types of nanoparticles. 
Type of nanoparticle Advantages Disadvantages 
Liposomes Load drugs with different solubilities 
*Neutral liposomes: Longer circulation half 
life, lower toxicity 
Rapid uptake by reticuloendothelial 
system 
Toxicity  
PLGA-nanoparticles High capacity of cargo 
Biocompatibility  
Different drug release profiles  
More in vivo 
Tests such as bone targeting and whole 
body biodistribution are needed 
Mesoporous silica 
nanoparticles  
Surface functionality 
Loading capacity 
Biocompatibility 
Bone-bioactivity related to ionic release 
The limited accessibility and high cost of 
organic template lead to its restricted use 
in practical applications 
There are not many studies done in vivo, 
and this can be challenging for MSN in 
clinical applications 
Metal- nanoparticles Hyperthermia treatment, inducing thermolysis 
by radiofrequency. 
Drug delivery, and can be used as magnetic 
resonance imaging (MRI) contrast agents 
They can spontaneously aggregate and 
cause vessel embolism after intravenous 
application 
Hydroxyapatite 
nanoparticles 
HA promotes osteoblast bioactivity, 
nanocarrier itself helps bone tissue to grow 
Its brittleness that makes it a hardly 
processed material.  
3. Conclusion 
Osteoporosis is a disease that has become a worldwide challenge, involving clinical, social and 
economic issues. Health systems and industry should be aware of this problem mainly because of the 
increase in life expectancy. This has a consequence of an ageing population more susceptible to 
suffer osteoporosis. Being osteoporosis a disease that affects a increasing proportion of the 
population, its treatment will have a great economic interest for the pharmaceutical industry. Current 
pharmacological therapy presents some limitations related to bioavailability issues and toxicity. The 
emergence of nanotechnology has provided new strategies for improving the properties of these 
therapies. Among different nanocarries bone-targeted nanoparticles represents a great potential for 
clinical applications in delivering drugs to bone niches. They are able to increase local drug 
concentration, reduce off-target side effects, and would lengthen the therapeutic window. However, 
only limited work has been reported so far on the release pattern and mechanism(s) involved, 
especially for the newly developed carriers. Consequently, more research is awaiting driven by the 
optimization of the carriers, focusing on drug release, stability and safety. Although more research is 
needed for clinical applications, there is an opportunity for prospective treatment options by 
enhancing nanotechnology. 
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